Form 4: Tandem Diabetes Care CEO Awarded Significant Equity Grants Under Long-Term Incentive Plan

Tandem Diabetes Care Inc.'s President and CEO, John F. Sheridan, was granted substantial performance and restricted stock units on May 30, 2025, aligning executive compensation with future company performance and shareholder value.

Summary

• John F. Sheridan, President & CEO and Director of Tandem Diabetes Care Inc. (TNDM), reported changes in his beneficial ownership of company securities.
• On May 30, 2025, Mr. Sheridan was awarded 119,204 Performance Stock Units (PSUs) and 119,206 Restricted Stock Units (RSUs) under the company's 2023 Long-Term Incentive Plan.
• The PSUs represent a contingent right to receive common stock based on the achievement of pre-defined performance metrics by December 31, 2027, with potential vesting ranging from 0% to 200% of the awarded amount.
• The RSUs grant a contingent right to receive common stock or cash, with 33% vesting on May 15, 2026, and the remainder vesting in eight equal quarterly installments thereafter.
• Following these transactions, Mr. Sheridan beneficially owns 96,327 shares of Common Stock directly, in addition to the newly awarded derivative securities.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a significant equity award to the CEO, aligning his incentives with long-term company performance and shareholder value. This is a standard and generally well-regarded practice for executive compensation.

Positives

• The equity awards (PSUs and RSUs) align the President & CEO's compensation directly with the company's long-term performance and shareholder interests.
• The performance-based nature of the PSUs incentivizes the achievement of specific company metrics, potentially driving future growth and value creation.
• The awards are part of a structured 2023 Long-Term Incentive Plan, indicating a formal approach to executive compensation and retention.

Negatives

• No specific negatives are directly stated in this Form 4 filing, as it primarily reports an equity award.

Risks

• The vesting of Performance Stock Units (PSUs) is contingent on achieving pre-defined performance metrics by December 31, 2027; if minimum metrics are not met, no PSUs will vest, potentially impacting executive compensation and retention.
• The vesting of both PSUs and Restricted Stock Units (RSUs) is subject to the awardee's continuing service through the respective measurement and vesting dates, posing a risk if the executive departs prior to these dates.

Future Outlook

The equity awards granted to the President & CEO are designed to incentivize future company performance and continued service through specific vesting schedules and performance measurement dates extending to December 31, 2027, for PSUs and quarterly installments for RSUs starting May 15, 2026.

Management Comments

• The awards were granted pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and related agreements.
• Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027.
• The number of shares issued for PSUs may range from 0% to 200% of the amount specified, based on company's actual performance relative to metrics and subject to continuing service.
• Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock or cash in lieu thereof, at the Issuer's discretion.
• RSUs vest as to thirty-three percent (33%) of the total on 5/15/2026, and the remaining shares vest in eight (8) equal quarterly installments thereafter.

Industry Context

This Form 4 filing reflects a standard practice in corporate governance where publicly traded companies use equity-based compensation, such as PSUs and RSUs, to align the interests of their top executives with those of shareholders. This is common across various industries, including medical devices and healthcare technology, to incentivize long-term performance and executive retention.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) as a significant component of executive compensation is a common practice among publicly traded companies, including those in the medical device and healthcare technology sectors, such as Medtronic, Dexcom, and Abbott Laboratories, which also utilize similar long-term incentive structures to motivate leadership.
• The structure of PSUs, with a performance measurement period extending to multiple years (e.g., until December 31, 2027), is consistent with industry best practices for encouraging sustained strategic execution rather than short-term gains.
• The vesting schedule for RSUs, with an initial cliff vesting followed by quarterly installments, is a standard approach designed to promote executive retention over several years.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards are designed to align the CEO's interests with shareholder value creation through performance-based incentives.
• Employees: While not directly impacting all employees, the long-term incentive plan for leadership can signal stability and a focus on future growth, which can indirectly benefit the broader employee base.
• Management: The awards provide significant long-term compensation and retention incentives for the President & CEO.

Next Steps

• Achievement of pre-defined performance metrics for PSUs by December 31, 2027.
• Vesting of 33% of RSUs on May 15, 2026, followed by eight equal quarterly installments.
• Continued service of John F. Sheridan through the respective vesting and measurement dates.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Equity Award, Performance Stock Units, Restricted Stock Units, Executive Compensation, Long-Term Incentive Plan, John F. Sheridan, CEO, Director, Beneficial Ownership